From: gsGator: an integrated web platform for cross-species gene set analysis
Rank | Set size | Overlap | P-value | Q-value | Mouse phenotype |
---|---|---|---|---|---|
1 | 79 | 10 | 9.9.E-21 | 7.5.E-17 | Abnormal blood coagulation |
2 | 73 | 5 | 1.9.E-09 | 7.0.E-06 | Increased bleeding time |
3 | 37 | 4 | 1.3.E-08 | 3.4.E-05 | Gastrointestinal hemorrhage |
4 | 150 | 5 | 7.0.E-08 | 1.2.E-04 | Increased leukocyte cell number |
5 | 57 | 4 | 7.9.E-08 | 1.2.E-04 | Abnormal cell adhesion |
6 | 1258 | 9 | 1.5.E-07 | 1.9.E-04 | Premature death |
7 | 75 | 4 | 2.4.E-07 | 2.6.E-04 | Decreased susceptibility to endotoxin shock |
8 | 80 | 4 | 3.1.E-07 | 2.9.E-04 | Thrombosis |
9 | 94 | 4 | 6.0.E-07 | 5.0.E-04 | Increased monocyte cell number |
10 | 30 | 3 | 1.3.E-06 | 9.1.E-04 | Abnormal cellular extravasation |
11 | 277 | 5 | 1.4.E-06 | 9.1.E-04 | Hemorrhage |
12 | 3 | 2 | 1.5.E-06 | 9.1.E-04 | Purpura |
13 | 33 | 3 | 1.7.E-06 | 1.0.E-03 | Decreased susceptibility to bacterial infection induced morbidity/mortality |
14 | 153 | 4 | 4.1.E-06 | 2.1.E-03 | Decreased erythrocyte cell number |
15 | 153 | 4 | 4.1.E-06 | 2.1.E-03 | Increased neutrophil cell number |
16 | 50 | 3 | 6.1.E-06 | 2.9.E-03 | Impaired macrophage chemotaxis |
17 | 51 | 3 | 6.5.E-06 | 2.9.E-03 | Decreased platelet aggregation |
18 | 6 | 2 | 7.2.E-06 | 3.0.E-03 | Abnormal circulating fibrinogen level |
19 | 7 | 2 | 1.0.E-05 | 3.8.E-03 | Uterine hemorrhage |
20 | 7 | 2 | 1.0.E-05 | 3.8.E-03 | Petechiae |
21 | 60 | 3 | 1.1.E-05 | 3.8.E-03 | Impaired neutrophil recruitment |
22 | 8 | 2 | 1.4.E-05 | 4.4.E-03 | Increased susceptibilityto infection induced morbidity/mortality |
23 | 65 | 3 | 1.4.E-05 | 4.4.E-03 | Abnormal leukocyte migration |
24 | 211 | 4 | 1.5.E-05 | 4.6.E-03 | Increased sensitivityto induced morbidity/mortality |
25 | 69 | 3 | 1.6.E-05 | 4.8.E-03 | Increased eosinophil cell number |
26 | 70 | 3 | 1.7.E-05 | 4.8.E-03 | Abnormal myelopoiesis |
27 | 9 | 2 | 1.7.E-05 | 4.8.E-03 | Hemothorax |
28 | 72 | 3 | 1.8.E-05 | 4.9.E-03 | Abnormal cell migration |
29 | 81 | 3 | 2.6.E-05 | 6.4.E-03 | Internal hemorrhage |
30 | 11 | 2 | 2.6.E-05 | 6.4.E-03 | Skin hemorrhage |
31 | 11 | 2 | 2.6.E-05 | 6.4.E-03 | Abnormal platelet aggregation |
32 | 86 | 3 | 3.1.E-05 | 7.3.E-03 | Decreased angiogenesis |
33 | 13 | 2 | 3.8.E-05 | 8.5.E-03 | Decreased susceptibility to induced choroidal neovascularization |
34 | 100 | 3 | 4.9.E-05 | 1.1.E-02 | Abnormal inflammatory response |
35 | 289 | 4 | 4.9.E-05 | 1.1.E-02 | Anemia |
36 | 15 | 2 | 5.0.E-05 | 1.1.E-02 | Pulmonary alveolar hemorrhage |
37 | 18 | 2 | 7.3.E-05 | 1.5.E-02 | Abnormal uterine environment |
38 | 20 | 2 | 9.1.E-05 | 1.8.E-02 | Abnormal physiological neovascularization |
39 | 21 | 2 | 1.0.E-04 | 1.9.E-02 | Hemoperitoneum |
40 | 22 | 2 | 1.1.E-04 | 2.0.E-02 | Pregnancy-related premature death |
41 | 22 | 2 | 1.1.E-04 | 2.0.E-02 | Abnormal platelet activation |
42 | 133 | 3 | 1.1.E-04 | 2.0.E-02 | Decreased platelet cell number |
43 | 24 | 2 | 1.3.E-04 | 2.3.E-02 | Increased susceptibility to fungal infection |
44 | 33 | 2 | 2.5.E-04 | 4.3.E-02 | Decreased cerebral infarction size |
45 | 180 | 3 | 2.7.E-04 | 4.6.E-02 | Pallor |